Drugs / 1278863
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00840320 | Mar → Sep 2009 | kidney disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1278863 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00840320 ↗ |
| Action | Inhibit | “through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs)” NCT00840320 ↗ |
| Route | Oral | “repeat oral doses” NCT00840320 ↗ |